Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
2 other identifiers
interventional
20
1 country
1
Brief Summary
The purpose of this study is to set an optimal measurement time for assessing driving ability in a driving simulator in healthy volunteers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2017
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 8, 2017
CompletedFirst Posted
Study publicly available on registry
September 11, 2017
CompletedStudy Start
First participant enrolled
September 22, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 25, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 25, 2017
CompletedFebruary 28, 2025
October 1, 2017
1 month
September 8, 2017
February 26, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Standard Deviation of Lateral Position (SDLP)
60 min.
Secondary Outcomes (2)
Distance Coefficient of Variation (DCV)
25 min.
Brake Reaction Time (BRT)
15 min.
Study Arms (1)
driving test
OTHERInterventions
Eligibility Criteria
You may qualify if:
- Body mass index (BMI) ≥18.5 and \<25.0 kg/m2 at screening inspection
- No visual impairment (enable to correct the vision with eyeglasses or contact lens)
- Receive a prior explanation on the study, able to accept its content, and capable to provide voluntary written consent for participation in this study
You may not qualify if:
- History of drug and food allergy
- Routinely drink alcohol before bedtime
- Inappropriate for enrollment in this study was judged by principal investigator or subinvestigator
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Taisho Pharmaceutical Co., Ltd.lead
- Nagoya Universitycollaborator
Study Sites (1)
Taisho Pharmaceutical Co., Ltd selected site
Fukuoka, Japan
Study Officials
- STUDY DIRECTOR
Shigeru Okuyama
Taisho Pharmaceutical Co., Ltd.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 8, 2017
First Posted
September 11, 2017
Study Start
September 22, 2017
Primary Completion
October 25, 2017
Study Completion
October 25, 2017
Last Updated
February 28, 2025
Record last verified: 2017-10